{
    "nct_id": "NCT02997982",
    "title": "Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer's Disease When Treated With Valaciclovir - Open Fas II Pilot Study (VALZ-Pilot)",
    "status": "COMPLETED",
    "last_update_time": "2020-04-01",
    "description_brief": "This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type. It is an open pilot trial where 36 participants will receive 4 weeks of Valaciclovir treatment. Participants will be investigated using different measures before and after the treatment period.",
    "description_detailed": "This study investigates the effects of valaciclovir treatment to individuals with Alzheimer's disease (AD) or Mild Cognitive Impairment of Alzheimer's Disease Type. It is an open pilot trial where 36 participants will receive 4 weeks of oral valaciclovir treatment. To find 36 persons fulfilling inclusion criteria, up to 120 persons will be screened. Important inclusion criteria are Herpes Simplex Virus (HSV) Immunoglobulin G (IgG)-positivity (HSV carriage), Apolipoprotein E allele 4 carriage and sufficient kidney function (estimated glomerular filtration rate above 30 ml/min). All participants must give their informed consent to participation.\n\nThe valaciclovir dose will be 500 mg three times daily the first week and 1000 mg three times daily week 2-4.\n\nParticipants will be investigated using different measures before and after the treatment period: Mini Mental State Examination to assess cognitive function, Cerebrospinal fluid biomarkers of Alzheimer's disease and \\[18F\\]-FHBG-PET/CT (9-\\[4-\\[18F\\]fluoro-3-(hydroxymethyl)butyl\\]guanine positron emission tomography/computed tomography)) to possibly indicate active HSV infection within the central nervous system.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Valaciclovir (prodrug of acyclovir)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is valaciclovir, an orally administered antiviral prodrug that is rapidly converted to acyclovir and acts by inhibiting herpesvirus DNA polymerase \u2014 i.e., it is a small\u2011molecule antiviral rather than a biologic. \ue200cite\ue202turn0search4\ue202turn0search2\ue201",
        "Act: Key trial details extracted from the trial report: this is an open phase II pilot of high\u2011dose valaciclovir given for 4 weeks to participants with early Alzheimer's disease / MCI\u2011AD, with cerebrospinal fluid (CSF) biomarkers (e.g., total tau, NfL, A\u03b2, p\u2011tau, inflammatory markers) and cognitive measures assessed before and after treatment. The study frames the intervention as testing whether antiviral treatment affects markers of AD/neurodegeneration and possible CNS herpesvirus activity. \ue200cite\ue202turn0search3\ue202turn0search1\ue201",
        "Act (drug identification): Valaciclovir is a small\u2011molecule prodrug of acyclovir (not a monoclonal antibody or vaccine), so it fits the 'small molecule' drug type. \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Classification decision: I classify this trial as 'disease-targeted small molecule' because the drug is a small\u2011molecule antiviral intended to target a hypothesized infectious contributor to Alzheimer's pathology and the outcomes are disease biomarkers (CSF markers) and cognition rather than only symptomatic cognitive enhancement or neuropsychiatric symptom management. \ue200cite\ue202turn0search3\ue201",
        "Reflect: Alternative interpretation \u2014 one could argue valaciclovir is not a classical anti\u2011amyloid/tau agent; however, the trial's aim (altering CSF biomarkers and detecting herpesvirus in CNS) indicates a disease\u2011modifying intent (targeting a putative causal/pathogenic mechanism), so 'disease-targeted small molecule' is the best fit. No placebo is mentioned in the description (open pilot), so placebo list is empty. \ue200cite\ue202turn0search3\ue201"
    ],
    "agent_type": "T) Other",
    "explanation_agent": [
        "Reason: The trial intervention is valaciclovir, an oral antiviral prodrug converted to acyclovir that inhibits herpesvirus DNA polymerase (a viral-targeted small\u2011molecule mechanism), and the trial tests whether antiviral treatment changes AD biomarkers and cognition. (Valacyclovir \u2192 acyclovir; nucleoside analog that after phosphorylation inhibits viral DNA polymerase.) \ue200cite\ue202turn0search1\ue202turn0search7\ue201",
        "Act: Extracted key facts from the trial and drug references: the VALZ\u2011Pilot is a high\u2011dose valaciclovir phase II pilot in early AD measuring CSF biomarkers (total tau, NfL, A\u03b2, p\u2011tau, inflammatory markers) and cognition; the drug is a small\u2011molecule antiviral (prodrug of acyclovir) whose target is viral DNA replication, not an amyloid/tau/host signaling pathway. \ue200cite\ue202turn0search4\ue202turn0search0\ue202turn0search2\ue201",
        "Reflect: CADRO categories (A\u2013S) enumerate pathways such as amyloid, tau, inflammation, metabolism, synaptic plasticity, etc.; they do not include a dedicated category for antiviral/anti\u2011infective targeting of viral replication. Because the mechanism (inhibiting herpesvirus DNA polymerase) is an anti\u2011infective action that does not map to Amyloid (A), Tau (B), Inflammation (F), or other listed CADRO mechanistic categories, the appropriate CADRO assignment is T) Other. (Referenced CADRO overview for context.) \ue200cite\ue202turn1search1\ue202turn1search10\ue201",
        "Output: {\"category\": \"T) Other\"} \u2014 Explanation: Valaciclovir is a small\u2011molecule antiviral (prodrug of acyclovir) that targets viral DNA polymerase (not a canonical AD molecular target in the CADRO list), and the VALZ\u2011Pilot tests antiviral effects on AD biomarkers; therefore the trial does not fit a specific CADRO mechanism category and is classified as T) Other. \ue200cite\ue202turn0search1\ue202turn0search4\ue202turn1search1\ue201"
    ]
}